Thyroid Nodule Methylation Analysis for Indeterminate FNA Results
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for thyroid nodules, such as fine needle aspiration (FNA) cytology, struggle with indeterminate results in 30% of cases, leading to unnecessary thyroid resections, as they fail to accurately distinguish between benign and malignant nodules due to overlapping cytological features and limitations in molecular testing based on DNA mutations and RNA instability.
Innovation Solution
A method involving DNA methylation analysis using sodium bisulfite treatment to convert unmethylated cytosines to uracil, allowing for the detection of methylation or unmethylation patterns at specific sites in thyroid nodule DNA, enabling more accurate differentiation between benign and malignant thyroid nodules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If fine needle aspiration (FNA) cytology is used to evaluate thyroid nodules, then the diagnostic procedure is simple and widely available, but the diagnostic accuracy is insufficient with 30% indeterminate results
Solution Approach 1:
The patent combines FNA cytology with molecular testing (DNA methylation analysis, gene expression profiling) to create a composite diagnostic approach. This merging allows the simple, widely-available FNA procedure to be enhanced with molecular markers that resolve indeterminate cases, thereby maintaining ease of operation while significantly improving diagnostic accuracy.
Solution Approach 2:
The patent introduces molecular biomarkers (methylation patterns, gene expression profiles) as intermediary elements between the initial FNA cytology result and the final diagnosis. These molecular intermediaries provide additional information that helps resolve indeterminate cases, bridging the gap between simple cytology and definitive diagnosis.
2Reliability
If thyroid resection is performed on indeterminate cases, then the risk of missing cancer is reduced, but unnecessary surgeries increase as 80% of resected nodules are benign
Solution Approach 1:
The patent performs molecular testing on FNA samples before committing to surgical resection. This preliminary molecular characterization provides additional diagnostic information that can distinguish benign from malignant nodules in indeterminate cases, allowing clinicians to avoid unnecessary surgeries while maintaining high cancer detection reliability.
Solution Approach 2:
The patent changes the diagnostic parameters by incorporating molecular markers (methylation status, gene expression levels) alongside traditional cytological features. This multi-parameter approach provides a more nuanced diagnosis, reducing the need for surgery in benign cases while maintaining sensitivity for detecting malignancy.
3Loss of information
If DNA mutation testing is used for FNA analysis, then molecular information is obtained, but the testing frequently fails due to lack of common mutations and presence of mutations in benign nodules
Solution Approach 1:
The patent shifts from testing for specific DNA mutations to testing for DNA methylation patterns and gene expression profiles. This parameter change is crucial because methylation patterns and expression profiles are more specific to malignancy and less prone to false positives compared to DNA mutations, which are frequently absent in cancer or present in benign nodules.
Solution Approach 2:
The patent replaces DNA mutation detection (sequence-based approach) with DNA methylation analysis and gene expression profiling (epigenetic and transcriptomic approaches). This substitution provides more reliable molecular diagnostic information because epigenetic modifications and expression patterns are more consistently altered in malignancy compared to point mutations.
4Loss of information
If RNA-based molecular testing is implemented, then transcriptional activity information is obtained, but the testing is complicated by RNA instability and has only 50% positive predictive value
Solution Approach 1:
The patent acknowledges that RNA is inherently unstable (short-lived) but uses this by performing rapid processing and analysis of RNA samples immediately after FNA collection. By accepting the transient nature of RNA and working within its short window of stability, the patent可以获得transcriptional activity information while managing the complexity through streamlined protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves diagnostic accuracy, reducing unnecessary surgeries by providing a highly sensitive and specific method to identify benign nodules, thereby improving patient outcomes and reducing healthcare costs.
Implementation Method 1
contacting the isolated thyroid nodule DNA with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA
Data Source
AI summary
The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.